Related Experiment Video

Updated: Apr 6, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists

Samantha Dias Suthar1, John P Middleton1

  • 1Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.

Seminars in Dialysis
|August 6, 2015
PubMed

Insights

Mineralocorticoid receptor antagonists (MRAs) may reduce cardiovascular risk in dialysis patients with advanced chronic kidney disease (CKD). However, concerns about efficacy and hyperkalemia risk in these patients require careful consideration.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Patients with advanced chronic kidney disease (CKD), especially end-stage renal disease (ESRD) requiring dialysis, face a high burden of cardiovascular disease.
  • Sudden cardiac arrest is the leading cause of mortality in advanced CKD patients.
  • Mineralocorticoid receptor antagonists (MRAs) are known to reduce cardiac risk in certain populations.

Purpose of the Study:

  • To review the potential cardiovascular benefits of MRAs in patients with ESRD.
  • To examine the risks associated with MRA use in patients with advanced CKD and reduced kidney function.
  • To address the conundrum of MRA use in ESRD patients given the high cardiovascular mortality.

Main Methods:

  • Review of existing literature on mineralocorticoid receptor antagonist therapy.
  • Analysis of cardiovascular outcomes and safety data in patients with end-stage renal disease.
  • Evaluation of the impact of reduced kidney function on MRA effectiveness and adverse events.

Main Results:

  • MRAs have demonstrated potential in reducing blood pressure and improving cardiac structure.
  • Preliminary data suggest improved survival with MRAs in ESRD patients.
  • Concerns persist regarding MRA effectiveness in patients with impaired kidney function and the risk of hyperkalemia.

Conclusions:

  • MRAs offer potential cardiovascular benefits for patients with advanced CKD and ESRD.
  • The risks of hyperkalemia and uncertain efficacy in renally impaired patients necessitate caution.
  • Further research is needed to optimize MRA use in this high-risk population.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

862
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K